Category Archives: Biotechnology

Zogenix, Inc. (ZGNX) is near the bottom in its industry group according to InvestorsObserver. ZGNX gets an overall rating of 35. That means it scores higher than 35 percent of stocks. Zogenix, Inc. gets a 27 rank in the Biotechnology industry. Biotechnology is number 28 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 35 would rank higher than 35 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Zogenix, Inc. (ZGNX) stock is trading at $20.22 as of 11:01 AM on Friday, Dec 18, a loss of -$0.08, or -0.39% from the previous closing price of $20.30. The stock has traded between $19.87 and $20.41 so far today. Volume today is less active than usual. So far 308,229 shares have traded compared to average volume of 863,394 shares.

Click Here to get the full Stock Score Report on Zogenix, Inc. (ZGNX) Stock.

Read more:
Is Zogenix, Inc. (ZGNX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

A rating of 77 puts aTyr Pharma Inc (LIFE) near the top of the Biotechnology industry according to InvestorsObserver. aTyr Pharma Inc's score of 77 means it scores higher than 77% of stocks in the industry. aTyr Pharma Inc also received an overall rating of 62, putting it above 62% of all stocks. Biotechnology is ranked 25 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

aTyr Pharma Inc (LIFE) stock has fallen -1.89% while the S&P 500 has risen 0.1% as of 11:10 AM on Wednesday, Dec 16. LIFE is down -$0.08 from the previous closing price of $4.37 on volume of 89,629 shares. Over the past year the S&P 500 has risen 15.84% while LIFE has risen 7.25%. LIFE lost -$2.65 per share the over the last 12 months.

Click Here to get the full Stock Score Report on aTyr Pharma Inc (LIFE) Stock.

Read the original post:
Is aTyr Pharma Inc (LIFE) the Top Pick in the Biotechnology Industry? - InvestorsObserver

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI), which became effective prior to market open today.

On the tails of a momentous year, we are pleased to be included in the Nasdaq Biotechnology Index, said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. Index inclusion recognizes our clinical progress and heightened investor awareness as we remain committed to rapidly advancing our pipeline in rare epilepsies and neuropsychiatric disorders.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company has also initiated a Phase 3 trial in status epilepticus. For more information visit http://www.marinuspharma.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, anticipate, estimate, intend, believe, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our clinical development plans for ganaxolone. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; clinical trial results may not support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; delays, interruptions or failures in the manufacture and supply of our product candidate; our ability to raise additional capital; the effect of the COVID-19 pandemic on our business, the medical community and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

Read the original post:
Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index - Business Wire

SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development.

We are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. Chriss leadership and deep manufacturing expertise, delivering both biologic and small molecule drugs to market, will be invaluable as we advance rezafungin, currently in pivotal Phase 3 trials, towards filing, and advance our antiviral conjugate (AVC) influenza program to IND filing.

Prior to joining Cidara, Mr. Kurtz served as head of commercial API manufacturing at Gilead Sciences, where he and his team played an instrumental role in the recent launches of products such as Biktarvy and Veklury (remdesivir). He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Mr. Kurtz held a number of leadership positions where he managed the development, scale-up and commercialization of drugs, biologics, medical devices and combination products at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk. He has successfully established supply capabilities and navigated products from late-stage development through approval, launch and sustained commercialization. Mr. Kurtz holds a B.S. in chemical engineering from the University of Colorado and is a graduate of the Westinghouse S3G Nuclear Engineering Program. He is also a proud veteran of the US Navy Submarine Force.

Mr. Kurtz commented, Cidaras commitment to the development of novel long-acting therapeutics for serious fungal and viral infections is of vital importance now more than ever. Rezafungin has the potential to become the new standard of care for the treatment and prevention of invasive fungal infections globally, and I look forward to leveraging my manufacturing and supply chain expertise to support a successful launch in the coming years. Additionally, Cidara is leveraging its Cloudbreak platform to create a new class of long-acting antivirals in influenza, RSV and HIV, and I am very excited to work with the Cidara team to advance these programs.

About RezafunginRezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

About Cloudbreak AVCsCidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak antiviral platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system. AVCs are initially being studied for the prevention and treatment of seasonal and pandemic influenza, with the potential to deliver universal protection for an entire flu season with a single dose. Cidara is also advancing preclinical and discovery AVC programs to target other life-threatening viruses, such as RSV, HIV and CoV, including COVID-19.

About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit http://www.cidara.com.

Forward-Looking StatementsThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as anticipates, expect, may, plan or will. Forward-looking statements in this release include, but are not limited to, statements related to the potential for rezafungin to transform the standard of care in treatment and prevention of invasive fungal infections, as well as the potential of the Cloudbreak platform to create a new class of long-acting AVCs in influenza, RSV and HIV. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidaras clinical trials, impacts of the COVID-19 pandemic on patient enrollment or other obstacles to the development of rezafungin and advancement of Cidaras other development programs. These and other risks are identified under the caption Risk Factors in Cidaras most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on managements assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com

MEDIA CONTACT:Karen OShea, Ph.D.LifeSci Communications(929) 469-3860koshea@lifescicomms.com

Read more:
Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations - BioSpace

Important applications of nanobiotechnology are in the areas of drug discovery, drug development, and drug delivery, and these are collectively referred to as nanodrugs. Nanobiotechnology, particularly the use of nanoparticles, has made significant contributions to drug discovery and development.

Nanoparticles In Biotechnology And Pharmaceuticals Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. It provides a clear understanding of the subject matter and has been accumulated by suing primary and secondary research techniques.The study report presents the market overview as market size, revenue, share, forecast and market drivers. In addition, report offers an in-depth analysis about the product scope and market opportunities and market risks for the participants. The report provides the description about the profile of the top manufacturers of Nanoparticles In Biotechnology And Pharmaceuticals Market.

Get the PDF Sample Copy of this report @: https://www.a2zmarketresearch.com/sample?reportId=88446

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report:

RocheGE HealthcareMerckNovartisAMAG PharmaceuticalsAmgenBausch & LombBiogenCelgeneGileadIpsenLeadiant BiosciencesnanoComposixPacira PharmaceuticalsPfizerShire

Global Nanoparticles In Biotechnology And Pharmaceuticals Market research report offers: Market definition of the global Nanoparticles In Biotechnology And Pharmaceuticals market along with the analysis of different influencing factors like drivers, restraints, and opportunities. Extensive research on the competitive landscape of global Nanoparticles In Biotechnology And Pharmaceuticals Identification and analysis of micro and macro factors that are and will effect on the growth of the market. A comprehensive list of key market players operating in the global Nanoparticles In Biotechnology And Pharmaceuticals market. Analysis of the different market segments such as type, size, applications, and end-users. It offers a descriptive analysis of demand-supply chaining in the global Nanoparticles In Biotechnology And Pharmaceuticals market. Statistical analysis of some significant economics facts Figures, charts, graphs, pictures to describe the market clearly.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Nanoparticles In Biotechnology And Pharmaceuticals market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Nanoparticles In Biotechnology And Pharmaceuticals markets trajectory between forecast periods.

Regions Covered in the Global Nanoparticles In Biotechnology And Pharmaceuticals Market Report 2021: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Get up to 30% Discount on this Premium Report @: https://www.a2zmarketresearch.com/discount?reportId=88446The cost analysis of the Global Nanoparticles In Biotechnology And Pharmaceuticals Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Reasons for buying this report: It offers an analysis of changing competitive scenario. For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies. It offers seven-year assessment of Nanoparticles In Biotechnology And Pharmaceuticals Market. It helps in understanding the major key product segments. Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities. It offers regional analysis of Nanoparticles In Biotechnology And Pharmaceuticals Market along with business profiles of several stakeholders. It offers massive data about trending factors that will influence the progress of the Nanoparticles In Biotechnology And Pharmaceuticals Market.

Table of Contents:Global Nanoparticles In Biotechnology And Pharmaceuticals Market Research Report 2021-2027Chapter 1 Nanoparticles In Biotechnology And Pharmaceuticals Market OverviewChapter 2 Global Economic Impact on IndustryChapter 3 Global Market Competition by ManufacturersChapter 4 Global Production, Revenue (Value) by RegionChapter 5 Global Supply (Production), Consumption, Export, Import by RegionsChapter 6 Global Production, Revenue (Value), Price Trend by TypeChapter 7 Global Market Analysis by ApplicationChapter 8 Manufacturing Cost AnalysisChapter 9 Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10 Marketing Strategy Analysis, Distributors/TradersChapter 11 Market Effect Factors AnalysisChapter 12 Global Nanoparticles In Biotechnology And Pharmaceuticals Market Forecast

Buy Exclusive Report @: https://www.a2zmarketresearch.com/enquiry?reportId=88446 If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us:Roger Smith1887 WHITNEY MESA DR HENDERSON, NV 89014sales@a2zmarketresearch.com+1 775 237 4147

About A2Z Market Research:The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Go here to see the original:
Nanoparticles In Biotechnology And Pharmaceuticals Market Witness the Growth of billion by 2026 | GE...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020. For this years re-ranking of the index, 100 biotech stocks were added and 16 were removed.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB), and which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting-edge cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA targeted CAR-T cell therapy for patients with multiple myeloma. This candidate is currently being studied in registrational clinical trials. To learn more about Legend Biotech, visit us on LinkedIn, or on Twitter @LegendBiotech or at http://www.legendbiotech.com.

Cautions Concerning Forward-Looking Statements

This information constitutes forward-looking statements relating to the publication of, and inclusion of Legend in, the NASDAQ Biotechnology Index. Such forward-looking statements reflect the current expectations of Legends management regarding this future event, and involve factors that may cause actual results to be different from such statements. In particular, Legends expectations could be affected by, among other things, changes in the eligibility criteria for the NASDAQ Biotechnology Index or their application.

The information in this press release speaks only as of the date hereof. Legend assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date.

Read the original:
Legend Biotech Added to the NASDAQ Biotechnology Index - Business Wire